Autopsy report · NCT06343376

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

“Manufacturing issues”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 1 month before it stopped.
• 1 participant enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Roswell Park Cancer Institute

Sponsor type

University, hospital or other

Conditions

Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent High Grade B-Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Transformed Chronic Lymphocytic Leukemia

Interventions

Biopsy; Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Cyclophosphamide

Participants

1

Sites

1

Countries

United States

Trials that died the same way

• Blood Sparing Strategies: Omni-stat Routinary Use in Cardiac Surgery. A Prospective Randomized Study.
  “Lack of product due to industrial changes in the manufacturing process altering the final product.” (60% match in meaning)
• The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy
  “Study product manufacturing suspended due to manufacturing problems, before initiation of study intervention.” (59% match in meaning)
• General Anesthesia Versus Awake Surgery in Resection of Gliomas and Metastases of Motor Areas
  “technical issues” (59% match in meaning)
• Effects of Interval Physical Training on Expiratory Flow Limitation in Recent Myocardial Infarction
  “technical problems in equipment” (58% match in meaning)
• The Effect of Optic Flow During Treadmill Walking on the Gait Pattern in People Post-stroke
  “Technical problems” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.